Guidance for antiretroviral therapy in HIV-infected infants less than 1 year of age
Forty per cent of HIV-infected children die before they reach their first year of life, mainly in the first 6 months. Data from the Children with HIV Early Antiretroviral Therapy (CHER) study indicate that even when infants appear well and their CD4 counts are >25% there is a 75% increased risk of mortality when antiretroviral therapy (ART) is deferred until threshold CD4 depletion occurs or clinical criteria are met.1 Even after starting ART, young infants have excess mortality within the first year of life. Every effort should therefore be made to identify HIV-infected infants as early as possible so that ART can be initiated without delay.
Southern African Journal of HIV Medicine Vol. 9 (4) 2008: pp. 34-35
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publishing rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Read more here: http://creativecommons.org/licenses/by/4.0/.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.